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Abstract
Main clinical and scientific aspects of methodology how to choose the right sample for 
testing to be involved in Plasma for Laboratory Diagnostics chapter as plasma is in use 
sufficiently widely. Different approach by clinical and research laboratories formed 
the necessity to discuss the basic laboratory terms and conditions to obtain correct 
results. Evaluation of preanalytical variables with impact on handling, processing 
and storage of samples with subsequent meaning for laboratory test results should 
be known by physicians, biomedical scientists, laboratory technicians and so on. The 
impact of chemical additives for diagnostics tools, the differences between plasma and 
serum samples for different laboratory tests and the subsequent analysis, manage-
ment and traceability of specimens with standardisation value should be taken into 
account.
Keywords: plasma, laboratory, preanalytics, diagnostics
1. Introduction
Summarised results for Plasma application for laboratory diagnostics in one chapter for qualita-
tive testing to be called “Handbook.” The understanding of laboratory phases, mainly preana-
lytics, is necessary both for clinical and research laboratories to obtain, compare and repeat or 
reproduce analysis. Main standardisation requirements are taken from clinical laboratories, 
and their approach should be useful for researchers to plan, organise the scientific work ful-
filling their research interest. This is the first attempt to improve research by the requirements 
for clinical laboratories.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Challenges and limitation for plasma use in laboratory testing
A literature review, metaanalysis and grounded theory of known methods and obtained results in 
laboratory practice worldwide with value of quality assurance are taken. The suppositional 
contents are as follows.
2.1. Preanalysis. Factors before testing
Human blood with additives for plasma preparation is a subject for variables, affecting pre-
analytical process, which takes app 50% of total laboratory turnaround (see Figure 1).
The preanalytical phase is divided into outside laboratory phase and inside laboratory phase 
for samples processing. There are no standards defining the quality of preanalytical phase. 
Known and following criteria should be taken as quality criteria in each individual labora-
tory. See Table 1.
Quality of the sample must be desired through all laboratory phases, starting from the pre-
analytical, which covers more than 50% of the total laboratory investigation circle [1].
2.2. Influence of unavoidable factors
Unavoidable factors such as age, race, gender and pregnancy are important considering clini-
cal chemistry and haematology subjects for testing and interpreting results. Biochemistry 
variables for serum iron [2], CK and creatinine [3] are always taken into account by gender per-
formance; other various substrates and enzyme activity or concentration (uric acid, bilirubin, 
alkaline phosphatase, etc.) are taken into account depending on age. Race differences should 
Figure 1. Preanalytical phase.
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be evaluated for blood count in haematology and enzymology within clinical chemistry, while 
the mean variable for plasma volume changes is pregnancy. During healthy pregnancy plasma 
volume increases by an average of about 1250 ml, with progressive increase up to 35th week of 
gestation, after which little or no further increase occurs. The frequently observed fall in plasma 
volume in the last 6 weeks of pregnancy is a false of measurement due to poor mixing of tracer 
when the woman lies supine, and this posture obstructs the circulation to the lower limbs [4]. 
The differential changes are biologically plausible. Erythrocytes mass rises proportionately to 
the need to carry the extra oxygen necessary in pregnancy [5]. The greater plasma volume is 
needed to cope with the very large increases in blood flow to organs which require different 
amount of extra oxygen. Increased plasma volume is greater than the increase in red blood cell 
mass, thus there is a fall in haemoglobin concentration, haematocrit and red blood cell count. It 
is worth to mention that despite this haemodilution, there is usually no change in mean corpus-
cular volume (MCV) or mean corpuscular haemoglobin concentration (MCHC) [6].
2.3. Meaning of variable subjects for plasma specimens
The variable diet, starvation, exercise are more important for serum analytes in clinical chem-
istry. Triglycerides, aspartate aminotransferase, bilirubin, glucose are very sensitive to diet 
and drinking habits. Starvation reduces blood cholesterol, triglycerides and urea concen-
trations. In contrast, creatinine and uric acid are elevated after long time (4 weeks) starva-
tion period. Changes may occur to an increase in reabsorption of the measured analyte or 
metabolism changes [1].
Process Importance Remarks for materials
Outside laboratory phase
Unavoidable factors Age, race, gender, pregnancy Fill request form properly
Avoidable, variable factors Caffeine, smoking, alcohol, drugs Ask patient and mark
Patient preparation Diet, starvation, exercise, altitude Ask patient and mark
Preparation of sampling Define and enter request into system, 
proper tube labelling
Request form and information system 
are mandatory. Patient and sample 
identification procedures
Sampling process Patient‘s ID, timing, use of tourniquet, site 
of sampling selection, position of needle, 
run order of tubes
Use of tubes, needles, disinfection 
materials strongly according procedures.
Transportation Difference of collecting and transporting 
tubes
Transporting containers, cooling systems 
according procedures
Laboratory phase
Sample treatment Registration, identification, centrifugation, 
distribution, extraction
Identification and registration procedures, 
authorised and secured laboratory 
information system
Sample/specimen storage Selection of site and temperature, timing, 
utilisation
Storage and freezing devices with 
temperature control according procedures
Table 1. Preanalytical phase and its importance for quality testing.
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Enzymes, such as pyruvate kinase, creatine kinase are raised from 2.5 to more than 4 times 
after a marathon rise. Sodium and potassium measurable in plasma after the same marathon 
rise elevate only by one fold. To reduce possible misinterpretation of laboratory findings, 
sampling after 12 h fasting and normal activity is highly recommended to ensure preanalyti-
cal procedures [1].
Significant changes may occur in blood at high altitude. β
2
-globulin and C reactive protein (CRP) 
may rise 43–65%. Ht and Hb are less sensitive—they increase only by 8%. The opposite phenom-
enon with decreasing values is demonstrated at plasma osmolality, plasma renin analytes [7].
Studies concluded that caffeine, smoking, alcohol or drugs intake may either decrease or 
increase different analytes [8]. Thus, it is highly recommended for blood sampling—the early 
morning before coffee, cigarette or other intakes were eliminated.
2.4. Interference factors. Lipaemia, haemolysis
Haemolysis is defined as the release of blood cells content into plasma or serum. The colour 
intensity depends form haemoglobin released from erythrocytes. Sometimes this can occur due 
to platelet and or granulocyte lysis. An effect of haemolysis is classified according to the differ-
ent mechanisms: increase of intracellular contents extracellularly; optical interference due to 
the haemoglobin colour; interference by intracellular contents with the different mechanisms 
of reaction. Laboratory should document haemolysed samples procedures as the responsibil-
ity of the laboratory diagnostics results belongs from the relevant interpretation of events [1].
After haemolysis, lipaemia is the most frequent interference factor that can influence results 
of clinical laboratory methods. Plasma or serum should be always considered due to vary-
ing degrees of an increased lipoprotein content. Turbidity is caused by an increased triglyc-
eride concentration, which may variate from slight to milky, and these samples are called 
lipaemic. The most common preanalytical cause of lipaemia is short time from meal taken 
or parenteral administration of lipid emulsions to blood sampling. The best way to detect 
the degree of lipaemia is measuring lipaemic index on analytical platforms. Laboratory staff 
should keep preanalytical procedures under control. Unlike for other interferences, lipaemia 
can be removed, and measurement can be done in a clear sample, using a protocol for remov-
ing lipids. On the other hand, sample has to be chosen carefully, since its dependency on the 
analytes that have to be tested [9].
2.5. Plasma or serum samples in vitro diagnostics. Advantages and disadvantages 
for use
Scientists and clinicians are still on debates—what type of sample a laboratory should use. 
Serum is still considered to be the gold standard remaining the required sample matrix for 
some biochemistry, immunology assays.
Both plasma and serum are liquid parts of the blood. The main difference between them per-
forms a clotting process. Plasma specimen is prevented from clotting and is more reflective of 
the systemic blood circulation in the body.
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There are diagnostically relevant differences between the results obtained from serum or 
plasma in laboratory. This happens due to several physiological and technical reasons:
• clotting factors: fibrinogen, platelets, glucose affecting analyte;
• analytes (potassium, lactate dehydrogenase, phosphate, ammonia, lactate, neurone-specif-
ic enolase, dopamine and serotonin) may be released from the cells during clotting process;
• the anticoagulant may interfere with the assay or contaminate with its cations: Lithium 
(heparinate) with flame photometry, when calibrated with lithium [1, 10].
There are different tubes for plasma or serum collection (see Figure 2) and sometimes differ-
ent applications due to the variable pathophysiological effects of platelets and clotting process 
to be involved for laboratory findings [11] (Table 2).
It is necessary to perform a rapid centrifugation to obtain more stable plasma. The extended 
contact with blood cells is complexable event including particles of the cells and metabolites 
after DNA, proteins degradation [12]. Thus, an immediate plasma centrifugation and extrac-
tion is desirable ASAP after blood collection.
There are proposed various methods and solutions for miniaturised blood plasma extraction. 
Macro-scale depending on the desired sampling volume: blood transfusion volume (500 ml), 
analytic venous sample (1–50 ml), or blood droplet from a finger-prick (up to 200 μl). Whatever 
the blood volume processed, the two conventional mechanisms—centrifugation or filtration—
exploited for plasma separation at the macroscale remain as necessity. Different solutions are 
Figure 2. Vacuum tubes for plasma collection. Images reproduced by kind permission of Becton, Dickinson and 
Company, All rights reserved. Unless otherwise noted, BD, the BD Logo and all other trademarks are property of Becton, 
Dickinson and Company.
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available for miniaturised blood plasma extraction within three main formats: the microfluidic 
chip format; the CD format and the paper format, based on different resources [13].
Remarks for testing:
2.6. Types of plasma samples. Additives for tubes
The colour codes of anticoagulants are described in ISO/CD 6710: EDTA = lavender/red; 
citrate 9:1 = light blue/green; citrate 4:1 = black/mauve; heparinate = green/orange; no addi-
tives (for serum) = red/white (ISO 6710). To obtain cell-free plasma for laboratory use, the 
anticoagulated blood should be centrifuged for at least 15 min at 2000–3000 × g, temperature 
should be set from 15 to 24°C [1].
2.6.1. EDTA
A salt of ethylene tetraacetic acid. Dipotassium (K2), tripotassium (K3) and disodium (Na2) 
are used. EDTAK2 or K3 blood is used in haematology and considerations which one addi-
tive to use are still under debates. The cell volume measured after centrifugation, decreases 
when concentration of this anticoagulant is higher and this is mainly seen with the tripo-
tassium (K3). This fact has been reported by different authors due to erythrocytes dehydra-
tion in hypertonic medium. Despite automated analysers work differently, but their MCV is 
not affected by K3-EDTA concentrations up to 10 times normal, while high concentrations of 
K2-EDTA, result a slight MCV increase [14, 15].
Functions Plasma Serum
Time saving ✓
Higher yield/specimen volume ✓
Prevention of clotting effect ✓
Prevention of changes induced with coagulation process ✓
Contamination with NH
4
+, Li+, Na+, K+ ✓ 
Inhibition of metabolic reactions by heparin ✓ 
Interference of ions distributed intra- and extra-cellular space ✓ 
Inhibition of enzymes by metal binding to EDTA and citrate ✓ 
Binding of ionised calcium to heparin ✓ 
Table 2. Advantages (marked) and disadvantages of plasma and serum (according Guder et al., 2016) [26].
Time saving. Serum sample must be allowed to clot, this time is variable from 10 min to 30 min and even longer.
Higher specimen volume or yield. Up to 20% more plasma than serum can be yielded after centrifugation.
In general, serum is used widely for the serological diagnosis of infectious diseases. There are some tests, that is, 
complement fixation or bacterial agglutination tests, where serum must be used only.
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2.6.2. Citrate
Trisodium citrate with 0.100–0.136 mol/L citric acid. Buffered citrate with 5.5–5.6:84 mmol/L 
trisodium citrate with 21 mmol/L citric acid. The International Society for Thrombosis and 
Haemostasis (ISH) recommended to use the Hepes-buffered citrate for all investigations of 
haemostasis. A mixture of one citrate part with nine parts of blood is recommended for coagu-
lation tests (ISO 6710), see: plasma for coagulation testing. A mixture of one citrate part with 
four parts of blood for ESR testing.
2.6.3. Heparin
12–30 IU/mL of sodium, lithium or ammonium salt of heparin, with 3–30 kDa of molecu-
lar mass. Calcium-treated heparin with concentration of 40–60 IU/mL of blood (dry hepa-
rinisation) and 8–12 IU/mL of blood (liquid heparinisation) are in use for ionised calcium 
determination.
2.6.4. Specificity for glucose samples (grey cap) for blood transporting stability only
Additives: potassium oxalate and sodium fluoride or sodium fluoride/Na2 EDTA or sodium 
fluoride (no anticoagulant, will result in serum sample).
It is worth to follow CLSI recommended Order of Draw [16].
Anticoagulants are useful to inhibit blood or plasma from clotting ensuring the quantity of 
additive has no impact for following analysis. Anticoagulation effect is achieved by binding 
calcium ions or by inhibiting thrombin activity. The very important step is mixing ensuring 
effective distribution of solid or liquid anticoagulant within the whole blood.
2.7. Plasma for coagulation tests
Coagulation tests (routine and special) in modern laboratory require a lot of knowledge, con-
tinuous education, sensitive automatic analytic system, broad spectrum reagents with differ-
ent purpose, quality manual and high-level communication with clinicians, phlebotomists 
and nurses with preanalytics algorithms detailed description or specimen collection and han-
dling instructions (Table 3).
The sample types for coagulation tests to use in laboratory medicine are: platelet rich plasma 
(PRP), platelet poor plasma (PPP) and whole blood (Figure 3).
PRP is a component of blood (plasma) with concentrations of platelets above normal val-
ues. PRP typically contains 3–8 times more platelets concentration than normal plasma. PRP 
is used for platelet function assays (diagnostics constitutional and acquired thrombopathy, 
follow-up on anti-platelet treatment) and in a variety of clinical applications, based on the 
premise that higher content of platelet-derived growth factors should promote better heal-
ing. Platelet derivatives represent a promising therapeutic modality, offering opportunities 
for treatment of wounds, ulcers, soft-tissue injuries, and various other applications in cell 
therapy [17].
Plasma for Laboratory Diagnostics
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Trueness of results in modern haemostaziology within modern laboratories depends on three 
major issues:
• Management preanalytics in the pre-laboratory phase and laboratory phase
• Sensitivity and possibilities of analytical system
• Interpretation of tests together with clinical data (clinical condition, anticoagulants, anti-
platelet treatment)
Specimen Tests Advantages Limitations Centrifugation
PPP PT, aPTT, 
fibrinogen, single 
coagulation 
factors assays
Representative of circulating 
blood
Common 
preanalytics
One step: 1500–2000 × g 
10–15 min
PRP Platelet function 
assays
Two aims possible:
(1) Diagnostics
(2) Therapy
Sensitive for 
handling
Two steps:
1st: slow centrifugation: 
170 × g calculated at the 
interface blood-plasma for 
10 min
to eliminate a red blood 
cells contamination.
2th: fast centrifugation: 
2200–2400 × g for 20 min.
Centrifugation at 4000 rpm
Whole 
blood
Platelet reactivity 
tests
Centrifugation is not required, 
the tests may be performed 
quickly. This sample type is used 
for POC analyser often.
Red and white 
cells can impact on 
the test results
Without special 
preparation
POC, point of care.
Table 3. Samples for coagulation.
Figure 3. Plasma for coagulation tests.
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2.7.1. Some preanalytics aspects
Though one mistake in preanalytics may distort the result and clinical interpretation may be 
wrong.
2.7.1.1. Clot in tube for coagulation tests?
The clot can be formatted in vitro in sample via this reasons:
• Slow blood flow into the tube
• Long pressure of tourniquet
• Significant (not acceptable for good practice) manipulative procedures with needle in vein
• Not enough mixing specimen with anticoagulant right away after blood drawing.
2.7.1.2. Serum or clotted sample?
If primary tube is taken inside laboratory, it is not difficult to determine whether blood was 
taken with proper anticoagulant. But errors may occur when samples get into with secondary 
tubes. It is not possible to state if proper anticoagulant or serum was taken instead of plasma. 
A serum does not has fibrinogen or other coagulation factors (FII, FV or FVIII) and high 
molecular weight of VWF as well. Serum analysis can give high levels of some factors (FVII) 
due to their activation and coagulation times testing for PT, aPTT and TT are not measured. 
False diagnosis can be established if plasma factor evaluation is wrong, as it often happens in 
the case of a certain type of Von Willebrand disease. Problems may occur with Lupus antico-
agulant determination.
Modern laboratories try to provide equipment which allows to detect the clots in specimen 
after the detection of significantly longer clotting times, but a visual check for a clot in a 
sample should be recommended or use of two wooden applicators/sticks for whole blood. If 
a clot is found, it is necessary to reject a sample from further investigation [18].
2.7.2. Haemolysis impact for coagulation
Reasons of In vitro haemolysis may be due to incorrect blood drawing or inadequate 
handling of blood after collection. Haemolysis can occur in vivo when cell lysis happens 
inside of vessels by autoimmune haemolysis, severe infections, DIC or post-transfusion 
reactions.
Analytical systems with mechanical clot detection principle are not affected by the interfer-
ence factors due to haemolysis, but results of tests may be not accurate because of products 
of cell lysis, including tissue factor which can activate coagulation. It is called a biological 
impact of haemolysis. Total effect of haemolysis may decrease the level of fibrinogen, but 
increase a level of D dimers. Prothrombin time may drop down because of lower concentra-
tion of fibrinogen; aPTT may lengthen or shorten depending which process prevails: decrease 
Plasma for Laboratory Diagnostics
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of fibrinogen or activation of coagulation. Haemolysis may distort other coagulation tests 
results, for instance decrease of antithrombin level [19].
If possible, the sample with grossly haemolysis must be rejected. If tests must be performed 
(e.g., in vivo haemolysis, it is not possible to take a new sample), for this case, it is recom-
mended to use mechanical detection systems, not excluding, that potential activation is pos-
sible as well.
Samples visually seem haemolysed via haemoglobin substitution, should not be rejected and 
must be analysed with mechanical or electromechanical clot detection method [20].
CLSI H21-A5:2008 Collection, Transport, and Processing of Blood Specimens for Testing 
Plasma-Based Coagulation Assays and Molecular Haemostasis Assays; Approved Guideline—
Fifth Edition standard says:
When evident, the presence of visible hemolysis, as evidenced by a pink to red tinge to the plasma, 
should be noted. Lysis of red blood cells and resultant release of intracellular or membrane components 
may cause clotting factor activation. This activation of coagulation factors may impact clotting time re-
sults, whether using an optical or mechanical end-point detection system, although there is discrepancy 
in the literature about the impact of hemolysis on clot-based assays.67,68 Until additional studies are pub-
lished, due to the potential with result interference, grossly hemolyzed samples should not be used. Pink 
or red-tinged plasma specimens may further impair end-point detection when using an optical system, 
due to its interference with light transmittance. Plasma may be tinged when there is red cell lysis or 
when the patient has been administered a hemoglobin substitute. Samples that appear hemolyzed due to 
the presence of hemoglobin substitutes are not a cause of specimen rejection, and these samples should 
ideally be tested with an instrument that uses mechanical end-point detection.
The best way to choose correct method when existing studies which were done with ana-
lytical systems and reagents combination and studied how haemolysis impact on routine 
(PT, APTT, fibrinogen) tests [21].
2.7.3. Specimen handling, storage, transportation
Transportation is a challenge of samples when specimens or samples are taken out to the 
external laboratories. Tubes should not be subjected to vibration, shaking, vortexing, continu-
ous mixing or agitation. Transport and sorting as bulk goods is not compatible with reliable 
coagulation diagnostics. Generally, blood samples for coagulation analyses should not be 
shaken, and dropped samples should be discarded [1].
The transportation often causes a delay of sample analysis, so customer must be sure that 
specimens will be analysed in time. Blood samples for coagulation diagnostics should be 
stored at room temperature (20–25°C) until analysis. Storage at lower temperature, or on ice, 
may strongly influence some of the coagulation assays [1].
A storage of uncentrifuged samples at room temperature up to 6 h may yield acceptable 
results, although a shorter delay is desirable. Whole blood assays should be performed within 
4 h after blood sampling. Data about handling and storage (time and temperature) of samples 
before transportation are different. Thus a laboratory must take decision how long the analy-
sis may delay [16].
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2.7.4. Continuous improvement of preanalytics in coagulation testing
Coagulation laboratory must regular review how to improve preanalytics in medical institution. 
Bostic et al. [19] studied, how possible to reduce quantity-not-sufficient specimens (QNS) via 
several methods and to measure effect of expired collection tubes on the amount of blood that 
can be drawn. During study period the rate of QNS specimens dropped from 0.7 to 0.3%. It was 
a significant difference in the amount of blood drawn into nonexpired vs. expired (Image 1).
The authors of study published a laboratory bulletin about Proper Blood Collection for 
Coagulation Studies [19].
2.8. Plasma for molecular-miRNR testing
Extracellular RNAs (exRNAs) found in biological samples have a potential to be used as clini-
cal biomarkers for various diseases as well as treatment monitoring. Differences in miRNA 
expression profiles are associated with tumorigenesis and can be used to classify cancer 
type, identify the developmental origin, select and monitor treatment [22]. Due to relatively 
easy acquisition and handling blood plasma is an attractive specimen to be used for miRNA 
extraction compared to tissue samples. Even though miRNAs have been a major focus for 
Image 1. Photograph of sodium citrate tubes containing blood from a single draw performed in a study period. The first 
three tubes from the left were expired and showed decreasing blood retrieval ability with older expiration dates (from 
right to left). The black arrow points to the minimum recommended fill level (etched line).
Plasma for Laboratory Diagnostics
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over a decade now, the majority of methodologies used for miRNA extraction and profiling 
come from a scientific research and are not approved for clinical use yet.
The major points affecting the miRNA extraction and application are choice of coagulant, 
plasma preparation and biological condition. Among the three most widely used anticoagu-
lants (EDTA, citrate, and heparin), EDTA is shown to be the least interfering chemical in the 
subsequent miRNA profiling, while heparin and citrate interfere with enzymes used for vari-
ous PCR [23]. Circulating miRNAs are either encapsulated in vesicles or found in complexes 
with proteins and lipoproteins, therefore are considered to be relatively stable. However, it is 
recommended that plasma preparation is done within 2 h of phlebotomy since blood cells start 
to release miRNAs into the collected sample causing changes in miRNA profile. Even mild 
haemolysis is also considered as an interfering factor associated with miRNA contamination 
from blood cells. Visual identification of minor haemolysis is difficult, therefore a simple mea-
surement of absorbance can be an accurate and time saving solution. Prepared plasma samples 
could be quickly tested for haemolysis by measuring the absorbance peak of free haemoglobin 
at 414 nm [24]. Plasma samples with A
414
 > 0.18 show signs of miRNA released from erythrocytes 
which might interfere with the overall profile of circulating miRNAs [24]. It is worth noting that 
lipaemia affects the A
414
 measurement; therefore, it is recommended to perform a second mea-
surement at A385 to detect the presence of lipaemia and use it to calculate a lipaemia-independent haemolysis score which could be adopted as a pre-analytical quality control [25]. Circulating 
miRNAs are often found in association with lipoproteins, therefore biological conditions, such 
as fasting, might have an impact on miRNA profiling [23]. The use of miRNA biomarkers in 
clinical setting is only starting therefore to standardise the pre-analytical procedure of sampling 
and sample preparation it is worth to have as little environmental variables as possible.
2.9. Quality manual for laboratory testing
A medical laboratory or clinical laboratory are laboratories for the examination of materials 
derived from the human body with a purpose of providing necessary information for diag-
nosis, prevention and treatment of disease as well as for follow up evaluation of health of a 
patient during the treatment. The ‘International Organization for Standardization’ (ISO) is an 
‘International Authority’ for setting up standard guidelines for various organisations and lab-
oratories. Each quality manual is based on internationally accepted standards and provides 
guidance for public health and clinical laboratories on writing policies and procedures that 
support a quality management system. It comprises a main document providing information 
and written procedures for laboratory quality (standard operating procedures, forms, and 
processes). It is worth to remember always to address quality manual before starting testing, 
sampling or consulting patients [24].
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